Are results of targeted gene sequencing ready to be used for clinical decision making for patients with acute myelogenous leukemia?

Current Hematologic Malignancy Reports

Volumn 8, Issue 2, 2013, Pages 149-155

  Rao, Arati V ^a   Smith, B Douglas ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

AML; Exome; Targeted gene sequencing; Transcriptome

Indexed keywords

CADHERIN; CADHERIN 24; DNA METHYLTRANSFERASE 3A; FLT3 LIGAND; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 123; MICRORNA; NUCLEOPHOSMIN; TRANSCRIPTOME; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANEUPLOIDY; ARTICLE; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CLINICAL DECISION MAKING; EPIGENETICS; EXOME; FRAMESHIFT MUTATION; GENE SEQUENCE; GENE STRUCTURE; GENOTYPE; HETEROZYGOTE; HUMAN; MISSENSE MUTATION; OVERALL SURVIVAL; PERSONALIZED MEDICINE; RNA SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

DECISION MAKING; DNA MUTATIONAL ANALYSIS; EXOME; GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA, MYELOID, ACUTE; SEQUENCE ANALYSIS, DNA;

EID: 84878754014     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-013-0161-6     Document Type: Article

References (23)

1. Surveillance, Epidemiology, and End Results (SEER) Program Populations (1969-2009) (www.seer.cancer.gov/popdata), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, January 2011.
2. Marcucci G, Haferlach T, Döhner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol. 2011;29(5):475-86.
3. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997;337(15):1021-8.
4. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409(6822):860-921.
5. Ley TJ, Mardis ER, Ding L, Fulton B, McLellan MD, Chen K, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature. 2008;456(7218):66-72.
6. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361(11):1058-66.
7. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363(25):2424-33.
8. Link DC, Schuettpelz LG, Shen D, Wang J, Walter MJ, Kulkarni S, et al. Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML. JAMA. 2011;305(15):1568-76.
9. Welch JS, Westervelt P, Ding L, Larson DE, Klco JM, Kulkarni S, et al. Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. JAMA. 2011;305(15):1577-84.
10. Teer JK, Mullikin JC. Exome sequencing: the sweet spot before whole genomes. Hum Mol Genet. 2010;19(R2):R145-51.
11. Grossmann V, Tiacci E, Holmes AB, Kohlmann A, Martelli MP, Kern W, et al. Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. Blood. 2011;118:6153-63.
12. Yan XJ, Xu J, Gu ZH, Pan CM, Lu G, Shen Y, et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet. 2011;43(4):309-15.
13. Greif PA, Yaghmaie M, Konstandin NP, Ksienzyk B, Alimoghaddam K, Ghavamzadeh A, et al. Somatic mutations in acute promyelocytic leukemia (APL) identified by exome sequencing. Leukemia. 2011;25:1519-22.
14. Feng H, Qin Z, Zhang X. Opportunities and methods for studying alternative splicing in cancer with RNA-Seq. Cancer Lett. 2012. doi: 10.1016/j.canlet.2012.11.010.
15. Greif PA, Eck SH, Konstandin NP, Benet-Pagès A, Ksienzyk B, Dufour A, et al. Identification of recurring tumor-specific somatic mutations in acute myeloid leukemia by transcriptome sequencing. Leukemia. 2011;25:821-7.
16. Ramsingh G, Koboldt DC, Trissal M, Chiappinelli KB, Wylie T, Koul S, et al. Complete characterization of the microRNAome in a patient with acute myeloid leukemia. Blood. 2010;116:5316-26.
17. Duncavage EJ, Abel HJ, Szankasi P, Kelley TW, Pfeifer JD. Targeted next generation sequencing of clinically significant gene mutations and translocations in leukemia. Mod Pathol. 2012;25(6):795-804.
18. Spencer DH, Abel HJ, Lockwood CM, Payton JE, Szankasi P, Kelley TW, et al. Detection of FLT3 internal tandem duplication in targeted, short-read-length, next-generation sequencing data. J Mol Diagn. 2013;15(1):81-93.
19. Walter MJ, Graubert TA, Dipersio JF, Mardis ER, Wilson RK, Ley TJ. Next-generation sequencing of cancer genomes: back to the future. Per Med. 2009;6(6):653.
20. Riva L, Luzi L, Pelicci PG. Genomics of acute myeloid leukemia: the next generation. Front Oncol. 2012;2:40.
21. Welch JS, Link DC. Genomics of AML: clinical applications of next-generation sequencing. Hematol Am Soc Hematol Educ Program. 2011;2011:30-5.
22. Mardis ER, Wilson RK. Cancer genome sequencing: a review. Hum Mol Genet. 2009;18(R2):R163-8.
23. Mardis ER. A decade's perspective on DNA sequencing technology. Nature. 2011;470(7333):198-203.